• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 


New Search Back to Search Results
Note: this medical device record is a supplement. The device description may have changed. Be sure to look at the original PMA to get an up-to-date view of this device.
 
DeviceUROLOGIX TARGIS SYSTEM FOR THE TREATMENT OF BPH
Classification Namesystem, hyperthermia, rf/microwave (benign prostatic hyperplasia),thermotherapy
Generic Namesystem, hyperthermia, rf/microwave (benign prostatic hyperplasia),thermotherapy
Applicant
Urologix, LLC
14405 21st avenue n.
minneapolis, MN 55447-2000
PMA NumberP970008
Supplement NumberS036
Date Received01/31/2008
Decision Date03/31/2008
Product Code
MEQ[ Registered Establishments with MEQ ]
Advisory Committee Gastroenterology/Urology
Supplement Typereal-time process
Supplement Reason change design/components/specifications/material
Expedited Review Granted? No
Combination Product No
Approval Order Statement 
Approval for changes to the materials, color, antenna design, coolant path functions and design of the cooled thermocath catheter. The device, as modified, will be marketed under the trade name ctc advance and is indicated to relieve symptoms and obstruction associated with benign prostatic hyperplasia (bph) and is indicated for men with prostatic urethra lengths of 3. 5 ? 5. 0 cm (model number tc1121c) or 4. 5+ cm (model number tf1221c).
-
-